Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation

• Status: Not yet recruiting
• Trial end date: 2025-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate limited course of treatment of Zebutinib combined with immunochemotherapy for patients with newly treated chronic lymphocytic leukemia without 17p-/TP53 mutation

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital of Southern Medical University

Criteria

Inclusion Criteria:

• CLL patients with indications for treatment according to iwCLL;

• CT/MRI shows measurable lesions;

• ECOG score is 0-2;

• No pregnancy plans during treatment

Exclusion Criteria:

• Richter transformation;

• 17p-/TP53 amplification ≥20% (FISH);

• Received steroids within 7 days before starting treatment;

• Have previously received treatments for chronic lymphocytic leukemia;

• Vaccine live attenuated vaccine within 4 weeks of randomization;

• Any life-threatening disease;

• Central nervous system leukemia;

• Apoplexy, history of intracranial hemorrhage;

• HIV or HCV or HBVpositive